Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Hepatic Artery Injection of
Open access · bronzeAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma.World journal of gastrointestinal surgery · 2023Trial
- The Development and Pilot Clinical Study of CD147 Targeted Antagonistic Peptide Probe for Tumor Imaging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Lactate mitochondrial oxidation drives stemness potential in metastatic breast cancer.Nature communications · 2025Article
- Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3-Targeted Single-Domain Antibody PET.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- The Anti-EMMPRIN Monoclonal Antibody hMR18-mAb Induces Tumor Dormancy and Inhibits the EMT Process in Human Carcinoma Cell Lines Co-Cultured with Macrophages.Biomedicines · 2025Article
- The pleiotropic roles of non-hormonal receptor basigin and regulatory microRNAs in breast cancer.NPJ breast cancer · 2025Review
- Prostate-specific membrane antigen-targeting radiopharmaceuticals: a new frontier in hepatic malignancies.Frontiers in oncology · 2025Review
- Article
- Review
- The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma.International journal of molecular sciences · 2023Review
- Site-Specific Radioiodination of Oligonucleotides with a Phenolic Element in a Programmable Approach.Molecules (Basel, Switzerland) · 2022Article
- Article
- The inhibiting effect of alpha-based TARE on embolized vessels and neovascularization.Frontiers in bioengineering and biotechnology · 2022Article
- Analysis of factors influencing the distribution of 131-I in combined treatment of Licartin with transcatheter arterial chemoembolization in primary hepatic carcinoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 8 institutions in 1 country.
Hui ChenKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Gang NanNational Translational Science Center for Molecular Medicine and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China.
Ding WeiNational Translational Science Center for Molecular Medicine and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China.
Ren-You ZhaiBeijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Ming HuangYunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Wu-Wei YangFifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Bao-Cai XingKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Xu ZhuKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Hai-Feng XuKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Xiao-Dong WangKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Xiao-Yong ZhangChina Nuclear Industry Beijing 401 Hospital, Beijing, China; and.
Bao-Rang ZhuFifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Peng LiuKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Guang CaoKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Song GaoKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Chun-Yi HaoKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Ren-Jie YangKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Jian-Hai GuoKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Xin ZhangKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Kun GaoBeijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Kun WangKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Jian-Feng WangBeijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Zi-Yu LiKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Lin-Zhong ZhuKey Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital, Beijing, China.
Rong DingYunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Jing LiFifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Ling ZhaoYunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Yu-Jun ShaoChina Nuclear Industry Beijing 401 Hospital, Beijing, China; and.
Hai-Chun LiuChina Nuclear Industry Beijing 401 Hospital, Beijing, China; and.
Jie-Lai XiaCollege of Military Preventive Medicine, Fourth Military Medical University, Xi'an, China.
Ling WangCollege of Military Preventive Medicine, Fourth Military Medical University, Xi'an, China.
Ling-Min KongNational Translational Science Center for Molecular Medicine and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China.
Zhi-Nan ChenNational Translational Science Center for Molecular Medicine and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China; hjbian@fmmu.edu.cn znchen@fmmu.edu.cn.
Huijie BianNational Translational Science Center for Molecular Medicine and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, China; hjbian@fmmu.edu.cn znchen@fmmu.edu.cn.
Peking University · CNPeking University Cancer Hospital · CNAir Force Medical University · CNChinese PLA General Hospital · CNKunming Medical University · CNBeijing Chao-Yang Hospital · CNChina National Nuclear Corporation · CNCapital Medical University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
This prospective nonrandomized, multicenter clinical trial was performed to investigate the efficacy and safety of
Indexed as
Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsAntibodies, MonoclonalCombined Modality TherapyHepatic ArteryHumansIodine RadioisotopesNeoplasm Recurrence, LocalProspective StudiesTreatment OutcomeAntibodies, MonoclonalIodine-131Iodine Radioisotopesmetuximab131I-labeled metuximabhepatocellular carcinomatranscatheter arterial chemoembolization
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.